BiotechTube

Darolutamide (Nubeqa, BAY1841788)

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Non-metastatic Castration-resistant Prostate Cancer

Conditions

Non-metastatic Castration-resistant Prostate Cancer

Trial Timeline

Aug 3, 2022 → Apr 29, 2027

NCT ID
NCT05348876

About Darolutamide (Nubeqa, BAY1841788)

Darolutamide (Nubeqa, BAY1841788) is a approved stage product being developed by Bayer for Non-metastatic Castration-resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05348876. Target conditions include Non-metastatic Castration-resistant Prostate Cancer.

What happened to similar drugs?

0 of 5 similar drugs in Non-metastatic Castration-resistant Prostate Cancer were approved

Approved (0) Terminated (0) Active (5)
🔄Bicalutamide + PlaceboAstraZenecaPhase 3
🔄Bicalutamide + PlaceboAstraZenecaPhase 3
🔄Bicalutamide + PlaceboAstraZenecaPhase 3
🔄Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigatorNovartisPhase 3
🔄Darolutamide (Nubeqa, BAY1841788) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06334120Pre-clinicalRecruiting
NCT05348876ApprovedRecruiting
NCT04464226Phase 3Recruiting

Competing Products

14 competing products in Non-metastatic Castration-resistant Prostate Cancer

See all competitors
ProductCompanyStageHype Score
Bicalutamide + PlaceboAstraZenecaPhase 3
40
Gefitinib, radiotherapyAstraZenecaPhase 1/2
32
Bicalutamide + PlaceboAstraZenecaPhase 3
40
Gefitinib, 5-fluorouracil, leucovorin and radiotherapyAstraZenecaPhase 1/2
24
Bicalutamide + PlaceboAstraZenecaPhase 3
40
AvelumabMerckPhase 2
35
Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigatorNovartisPhase 3
47
HSP-130PfizerPhase 2
35
AK104 + LenvatinibAkesoPhase 2
39
Darolutamide (Nubeqa, BAY1841788)BayerPre-clinical
30
Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + ApalutamideBayerPre-clinical
23
Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + ApalutamideBayerPre-clinical
23
Darolutamide (Nubeqa, BAY1841788) + PlaceboBayerPhase 3
37
Apalutamide + Darolutamide (BAY 1841788) + EnzalutamideBayerPre-clinical
23